Edison Investment Research raised its net present value (NPV) estimates for Norway's Bionor Pharma (OSE: BIONOR) after the company updated its net cash position.
The broker in a research note raised its NPV estimates to 1 billion Norwegian kroner ($121.7 million) from 993 million kroner.
The broker said net cash of 55.5 million kroner at end June should be sufficient to fund operations into early 2016, beyond the next key data for Vacc-4x, the company’s HIV vaccine, expected in the second half of 2015.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze